Edition:
United Kingdom

Lannett Company Inc (LCI.N)

LCI.N on New York Stock Exchange

12.80USD
19 Jul 2018
Change (% chg)

$0.10 (+0.79%)
Prev Close
$12.70
Open
$12.70
Day's High
$12.95
Day's Low
$12.55
Volume
72,777
Avg. Vol
115,081
52-wk High
$30.35
52-wk Low
$12.20

Chart for

About

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June... (more)

Overall

Beta: 2.73
Market Cap(Mil.): $784.83
Shares Outstanding(Mil.): 37.28
Dividend: --
Yield (%): --

Financials

  LCI.N Industry Sector
P/E (TTM): -- 30.93 32.76
EPS (TTM): -0.03 -- --
ROI: -0.04 15.07 14.61
ROE: -0.10 16.60 16.34

BRIEF-Lannett Receives FDA Approval For Dronabinol Capsules

* LANNETT COMPANY INC - RECEIVED APPROVAL OF ABBREVIATED NEW DRUG APPLICATION FOR DRONABINOL CAPSULES USP, 2.5 MG, 5 MG AND 10 MG

21 May 2018

BRIEF-Lannett Reports Q3 Adjusted Earnings Per Share $0.80

* LANNETT ANNOUNCES FISCAL 2018 THIRD-QUARTER FINANCIAL RESULTS

07 May 2018

BRIEF-Lannett Acquires Portfolio Of Generic Products From Endo International

* LANNETT ACQUIRES PORTFOLIO OF GENERIC PRODUCTS FROM ENDO INTERNATIONAL

07 May 2018

BRIEF-Lannett Appoints Patrick Lepore Chairman Of Board

* LEPORE WILL SUCCEED JEFFREY FARBER, WHO WILL REMAIN A MEMBER OF BOARD Source text for Eikon: Further company coverage:

30 Apr 2018

BRIEF-Lannett Company Files For Potential Mixed Shelf Offering

* LANNETT COMPANY INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2GblSC4) Further company coverage:

13 Feb 2018

BRIEF-Lannett Co Reports Q2 Earnings Per Share $0.37

* LANNETT ANNOUNCES FISCAL 2018 SECOND-QUARTER FINANCIAL RESULTS; REPORTS RECORD REVENUES, STRONG EARNINGS

07 Feb 2018

BRIEF-Lannett Co Voluntarily Pays Down $25 Mln Of Term Loans

* LANNETT COMPANY SAYS $25 MILLION PAY DOWN OF TERM LOANS WILL SAVE CO ABOUT $1.7 MILLION IN ANNUALIZED CASH INTEREST EXPENSE, AT CURRENT RATES Source text for Eikon: Further company coverage:

07 Feb 2018

BRIEF-Lannett Enters Into Consulting Agreement With Former CEO, Bedrosian

* LANNETT ENTERS INTO CONSULTING AGREEMENT WITH FORMER CEO, ARTHUR BEDROSIAN

01 Feb 2018

Competitors

  Price Chg
AbbVie Inc (ABBV.N) $89.95 -4.45
Pfizer Limited (PFIZ.NS) Rs2,555.45 -2.50
Dr.Reddy's Laboratories Ltd (REDY.NS) Rs2,056.80 +27.60

Earnings vs. Estimates